First phase hepatitis c viral kinetics in previous nonresponders patients

Journal of Viral Hepatitis

Volumn 10, Issue 1, 2003, Pages 43-49

  Cotler, Scott J ^a,d   Layden, J E ^b   Neumann, A U ^c   Jensen, D M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d NONE   (United States)

Author keywords

Interferon therapy; Nonresponder patients; Viral kinetics

Indexed keywords

CONSENSUS INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MODELS, STATISTICAL; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0345505664     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00401.x     Document Type: Article

References (32)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Engl J Med 1999; 341: 556-562.
2. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-1233.
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
6. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis 1996; 15: 5-14.
7. Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-1127.
8. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.
9. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-787.
10. Poynard T, Marcillin P, Lee SS et al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
11. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
12. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
14. Heathcote EJL, Keeffe EB, Lee SS et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27: 1136-1143.
15. Cheng SJ, Bonis PAL, Lau J, Pham NO, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-240.
16. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-708.
17. Kohara M, Tanaka T, Tsukiyama-Kohara K et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-alfa with different virologic kinetics. J Infect Dis 1995; 172: 934-938.
18. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
19. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
20. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
21. Yasui K, Okanoue T, Murakami Y et al. Dynamics of hepatitis C viremia following interferon-alfa administration. J Infect Dis 1998; 177: 1475-1479.
22. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.
23. Zeuzem S, Schmidt JM, Lee JH, Von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.
24. Layden JE, Neumann AU, Reddy KR, Layden TJ. The effect of 1st phase HCV viral kinetic parameters on the 2nd phase slope. The American Association for the Study of Liver Diseases Single Topic Conference on Hepatitis. 2001.
25. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-964.
26. Layden JE, Layden TJ, Reddy KR, Levi-Drummer R, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepatitis 2002; 9: 340-5.
27. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
28. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.
29. Ramratnam B, Bonhoeffer S, Binley J et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-1785.
30. Layden TJ. Principles of interferon induction therapy. Am J Med 1999; 107(6B): 71S-73S.
31. Bekkering FC, Neumann AU, Levi-Drummer R, Brouwer JT, Schalm SW. In-vivo longitudinal changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients [Abstract]. Hepatology 2000; 32: 367A.
32. Neumann AU, Layden TK, Reddy KR, Levi-Drummer R, Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response (SVR) following consensus interferon (Infergen) treatment for chronic hepatitis C and is determined by genotype but not by dose [Absract]. Hepatology 2000; 32: 356A.